4.7 Letter

Early clinical experience with imatinib in COVID-19: Searching for a dual effect

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Multidisciplinary Sciences

Identification of SARS-CoV-2 inhibitors using lung and colonic organoids

Yuling Han et al.

Summary: Researchers have developed lung and colonic organoid models using human pluripotent stem cells, which demonstrate susceptibility to SARS-CoV-2 infection. These models are valuable for studying the infection of the virus and screening drugs, with potential therapeutic implications for COVID-19.

NATURE (2021)

Editorial Material Critical Care Medicine

Immunomodulation in COVID-19

Nicholas E. Ingraham et al.

LANCET RESPIRATORY MEDICINE (2020)

Letter Immunology

Imatinib for COVID-19: A case report

Alejandro Morales-Ortega et al.

CLINICAL IMMUNOLOGY (2020)

Letter Oncology

Imatinib is not a potent anti-SARS-CoV-2 drug

Helong Zhao et al.

LEUKEMIA (2020)

Article Physiology

Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury

Alicia N. Rizzo et al.

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2015)